SCM
IBRX icon

Stevens Capital Management’s ImmunityBio IBRX Stock Holding History

Stevens Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,639
Closed -$52K – 943
2017
Q1 		$52K Buy
+14,639
New +$72.3K ﹤0.01% 833

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Stevens Capital Management's IBRX Position: Q2 2017 in Review

Stevens Capital Management sold out of ImmunityBio (IBRX) in Q2 2017, closing a stake of 14,639 shares — an estimated $52K sold.

Stevens Capital Management first reported a position in IBRX in Q1 2017 and held it in 1 quarter. The position peaked at $52K in Q1 2017. 58 funds tracked by Wall St. Rank hold IBRX as of Q2 2017.

  • Stevens Capital Management reported no remaining ImmunityBio position as of Q2 2017 after selling out during the quarter.
  • Stevens Capital Management sold 14,639 ImmunityBio shares in Q2 2017, an estimated $52K.
  • Stevens Capital Management first reported a position in ImmunityBio in Q1 2017 and held it in 1 quarter.
  • Stevens Capital Management's ImmunityBio position peaked at $52K in Q1 2017.
  • 58 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2017.

Based on Stevens Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.